Drug treatment of stroke. Current status and future prospects.

abstract：:Antihistamines are a diverse group of drugs which possess the ability to inhibit various histaminic actions. By and large, they bear a certain structural resemblance to histamine, and act principally to prevent histamine-receptor interaction through competition with histamine for histamine receptors. Consequently, the...

journal_title：Drugs

authors： Pearlman DS

更新日期：1976-01-01 00:00:00

abstract：:The naturally occurring catecholamines, noradrenaline, adrenaline and dopamine, have been found in a wide range of animal and vegetable tissues, but are particularly associated with nervous tissue in animals. Of the many processes affecting the response to stimulation of catecholamine containing nerves, the synthesis ...

journal_title：Drugs

authors： Laverty R

更新日期：1978-11-01 00:00:00

abstract：:Teneligliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that was approved for the treatment of type 2 diabetes mellitus (T2DM) in Japan and Korea and is being researched in several countries. Teneligliptin is a potent, selective, and long-lasting DPP-4 inhibitor with a t½ of approximately 24 h and unique pharmacok...

journal_title：Drugs

authors： Ceriello A,De Nigris V,Iijima H,Matsui T,Gouda M

更新日期：2019-05-01 00:00:00

abstract：:Antibacterial activities of cefotaxime and its major metabolite, desacetylcefotaxime, against 178 strains (of 10 species) were assessed in terms of minimum inhibitory concentrations (MIC50 and MIC80), and were compared with those of cefoperazone and ceftazidime. The activity of desacetylcefotaxime was several times le...

journal_title：Drugs

authors： Oizumi K,Hayashi I,Aonuma S,Konno K

更新日期：1988-01-01 00:00:00

abstract：:A number of oral and inhaled drugs are available for the long term management of patients with persistent asthma, yet the disease continues to be associated with significant morbidity and mortality. Over the past years, inhaled glucocorticoids have become established as a cornerstone of maintenance therapy because of ...

journal_title：Drugs

authors： Fabbri LM,Piattella M,Caramori G,Ciaccia A

更新日期：1996-01-01 00:00:00

abstract：:Antiviral therapy has in the past met with limited success and only a few antiviral drugs have been available. The human immunodeficiency virus (HIV) epidemic has created an urgent need for the development of antiviral therapy against this infection. HIV replication offers several targets for inhibitory compounds, the...

journal_title：Drugs

authors： Sandström E,Oberg B

更新日期：1993-04-01 00:00:00

abstract：:An increase in serum digoxin concentration occurs in 90% of patients given quinidine. On average, the serum digoxin doubles during treatment with therapeutic doses of quinidine. Almost every patient treated with quinidine will have a decrease in the renal clearance of digoxin and many will have a decrease in the volum...

journal_title：Drugs

authors： Bigger JT Jr,Leahey EB Jr

更新日期：1982-09-01 00:00:00

abstract：:The pharmacokinetics of cefoperazone in normal subjects, and in patients with hepatic and renal dysfunction are reviewed. After intravenous administration of 2 g of cefoperazone, levels in serum ranged from 202 to 375 microgram/ml depending on the period of drug administration. After intramuscular injection of 2 g of ...

journal_title：Drugs

authors： Craig WA,Gerber AU

更新日期：1981-01-01 00:00:00

abstract：:In the 30 years since the rabbit antithymocyte globulin (rATG) Thymoglobulin(®) was first licensed, its use in solid organ transplantation and hematology has expanded progressively. Although the evidence base is incomplete, specific roles for rATG in organ transplant recipients using contemporary dosing strategies are...

journal_title：Drugs

authors： Mohty M,Bacigalupo A,Saliba F,Zuckermann A,Morelon E,Lebranchu Y

更新日期：2014-09-01 00:00:00

abstract：:Drotrecogin alfa (activated), recombinant human activated protein C, inhibits coagulation and inflammation and promotes fibrinolysis in patients with severe sepsis. 850 patients with severe sepsis treated with intravenous drotrecogin alfa (activated) 24 microg/kg/h for 96 hours had a significantly greater reduction in...

journal_title：Drugs

authors： Lyseng-Williamson KA,Perry CM

更新日期：2002-01-01 00:00:00

abstract：:A fixed-dose combination tablet of the hepatitis C virus (HCV) NS5A inhibitor elbasvir and the HCV NS3/4A protease inhibitor grazoprevir (elbasvir/grazoprevir; Zepatier™) is under development by Merck. Oral elbasvir/grazoprevir 50/100 mg once daily has been approved in the USA for the treatment of adults with chronic ...

journal_title：Drugs

authors： Keating GM

更新日期：2016-04-01 00:00:00

abstract：:Eravacycline (Xerava™), a novel fully synthetic fluorocycline, consists of the tetracyclic core scaffold with unique modifications in the tetracyclic D ring; consequently, it exhibits potent in vitro activity against Gram-positive and -negative bacterial strains expressing certain common tetracycline-specific acquired...

journal_title：Drugs

authors： Scott LJ

更新日期：2019-02-01 00:00:00

abstract：:Intravenous landiolol [Rapibloc® (EU)], an ultra short-acting highly cardioselective β1-blocker, is approved in the EU for the rapid short-term control of tachyarrhythmias in the perioperative and intensive care settings. It has long been used in Japan to treat perioperative tachyarrhythmias. The efficacy of landiolol...

journal_title：Drugs

authors： Syed YY

更新日期：2018-03-01 00:00:00

abstract：:Everolimus is an immunosuppressant that blocks growth factor-mediated proliferation of haematopoietic and nonhaematopoietic cells. Oral everolimus 0.75 or 1.5mg twice daily significantly reduced the incidence of the primary composite endpoint, efficacy failure 6 months after transplantation, compared with azathioprine...

journal_title：Drugs

authors： Chapman TM,Perry CM

更新日期：2004-01-01 00:00:00

abstract：:Lefamulin is a novel oral and intravenous (IV) pleuromutilin developed as a twice-daily treatment for community-acquired bacterial pneumonia (CABP). It is a semi-synthetic pleuromutilin with a chemical structure that contains a tricyclic core of five-, six-, and eight-membered rings and a 2-(4-amino-2-hydroxycyclohexy...

journal_title：Drugs

authors： Zhanel GG,Deng C,Zelenitsky S,Lawrence CK,Adam HJ,Golden A,Berry L,Schweizer F,Zhanel MA,Irfan N,Bay D,Lagacé-Wiens P,Walkty A,Mandell L,Lynch JP 3rd,Karlowsky JA

更新日期：2020-11-28 00:00:00

abstract：:Resting heart rate is associated with cardiovascular and all-cause mortality, and the mortality benefit of some cardiovascular drugs seems to be related in part to their heart rate-lowering effects. Since it is difficult to separate the benefit of heart rate lowering from other actions with currently available drugs, ...

journal_title：Drugs

authors： DiFrancesco D,Camm JA

更新日期：2004-01-01 00:00:00

abstract：:Multiple sclerosis (MS) is thought to be a chronic inflammatory disorder of the CNS. The past decade has seen the introduction of the new immunomodulatory drugs, interferon (IFN)-beta and glatiramer acetate, that have considerably improved the therapeutic options for this often disabling disease. The efficacy of these...

journal_title：Drugs

authors： Flachenecker P,Rieckmann P

更新日期：2003-01-01 00:00:00

abstract：:Meloxicam is a new nonsteroidal anti-inflammatory drug (NSAID) developed for the treatment of rheumatoid arthritis and osteoarthritis. It has greater in vitro and in vivo inhibitory action against the inducible isoform of cyclo-oxygenase (COX-2), which is implicated in the inflammatory response, than against the const...

journal_title：Drugs

authors： Noble S,Balfour JA

更新日期：1996-03-01 00:00:00

abstract：:Although vascular smooth muscle cells (SMCs) play a key role in the development of atherosclerotic lesions, they are not a homogeneous cell type. Myosin has been used as a marker of SMC differentiation in order to identify distinct SMC populations in the adult rabbit aorta. The medial layer of the normal adult aorta c...

journal_title：Drugs

authors： Pauletto P,Da Ros S,Zoleo M

更新日期：1994-01-01 00:00:00

abstract：:Slowing of nerve conduction, a hallmark of both experimental and human diabetic neuropathy, is improved or corrected by aldose reductase inhibitors such as sorbinil. Animal experiments suggest that a myo-inositol-related defect in nerve sodium-potassium adenosine triphosphatase (ATPase) is responsible for the acute re...

journal_title：Drugs

authors： Greene DA

更新日期：1986-01-01 00:00:00

abstract：:The potential interaction between nimesulide, a nonsteroidal anti-inflammatory drug, and digoxin was studied in 9 patients [6 males, 3 females; mean age 67 (range 57 to 70) years] with mild heart failure. All patients were receiving maintenance therapy with digoxin (0.25 mg/day, orally) and were treated with oral nime...

journal_title：Drugs

authors： Baggio E,Maraffi F,Montalto C,Nava ML,Torti L,Casciarri I

更新日期：1993-01-01 00:00:00

abstract：:The bacteria most commonly responsible for early-onset (materno-fetal) infections in neonates are group B streptococci, enterococci, Enterobacteriaceae and Listeria monocytogenes. Coagulase-negative staphylococci, particularly Staphylococcus epidermidis, are the main pathogens in late-onset (nosocomial) infections, es...

journal_title：Drugs

authors： Fanos V,Dall'Agnola A

更新日期：1999-09-01 00:00:00

abstract：:Brodalumab (Lumicef(®)) is a human monoclonal immunoglobulin G antibody that is being developed by Kyowa Hakko Kirin in Japan, where it has been approved for the treatment of psoriasis vulgaris, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma. Brodalumab binds with high affinity to interleukin (IL)-...

journal_title：Drugs

authors： Greig SL

更新日期：2016-09-01 00:00:00

abstract：:The European Commission and the European Parliament have acknowledged the specific need for a proper evaluation of new drugs in children. The evaluation of the antiepileptic drugs (AEDs) available on the market illustrates the deficit in therapeutic trials for childhood epilepsy syndromes. Currently, the development o...

journal_title：Drugs

authors： Chiron C,Dulac O,Pons G

更新日期：2008-01-01 00:00:00

abstract：:Approximately 15% of patients with ulcerative colitis will experience a severe episode requiring hospitalization. Although intravenous corticosteroids are the current first-line therapy for these patients, about 30% of patients do not respond to corticosteroids and require either an alternative anti-inflammatory agent...

journal_title：Drugs

authors： Moss AC,Peppercorn MA

更新日期：2008-01-01 00:00:00

abstract：OBJECTIVE:The aim of this article is to review data on the efficacy and safety of montelukast in the treatment of children with asthma. METHODOLOGY:Available published literature, including published abstracts, is reviewed. RESULTS:In patients aged 6 to 14 years with asthma (n = 27), montelukast 5mg demonstrated a si...

journal_title：Drugs

authors： Becker A

更新日期：2000-01-01 00:00:00

abstract：:Alirocumab (Praluent®) is a fully human monoclonal antibody developed by Regeneron Pharmaceuticals and Sanofi that has been approved in the US as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolaemia (HeFH) or clinical atherosclerotic car...

journal_title：Drugs

authors： Markham A

更新日期：2015-09-01 00:00:00

abstract：:A somatropin preparation (Zorbtive) produced by recombinant DNA technology has been evaluated in patients with short bowel syndrome. Somatropin is thought to enhance intestinal adaptation in this condition through direct or indirect effects on the intestine. In a randomised, double-blind study in patients with short b...

journal_title：Drugs

authors： Keating GM,Wellington K

更新日期：2004-01-01 00:00:00

abstract：:Currently available quinolones are either inactive or marginally active against anaerobic bacteria. This review summarises the in vitro activity of currently available as well as experimental quinolones against clinically significant anaerobic bacteria. Quinolones with low activity against anaerobes include ciprofloxa...

journal_title：Drugs

authors： Appelbaum PC

更新日期：1995-01-01 00:00:00

abstract：:Vildagliptin (Galvus) is an antihyperglycaemic agent that selectively inhibits the dipeptidyl peptidase-4 (DPP-4) enzyme. Such inhibition prevents the degradation of the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). This results in improved glycaemic control ...

journal_title：Drugs

authors： Croxtall JD,Keam SJ

更新日期：2008-01-01 00:00:00